Navigation Links
McGill, Quebec biotech firm partner for new bone-disease treatment
Date:3/5/2010

This release is available in French.

Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth. While osteoporosis later in life is an example of bone density deficiency, this research applies to patients, especially children, who never properly mineralized their skeletons to begin with.

The field is known as biomineralization and it involves cutting-edge, nanotech investigation into the proteins, enzymes and other molecules that control the coupling of mineral ions (calcium and phosphate) to form nano-crystals within the bone structure. The treatment, enzyme replacement therapy to treat hypophosphatasia, is currently undergoing clinical testing in several countries including Canada. Hypophosphatasia is a rare and severe disorder resulting in poor bone mineralization. In infants, symptoms include respiratory insufficiency, failure to thrive and rickets.

Luckily, McKee explains that "Montreal is a world-leader in the biomineralization field, having attracted some of the top international specialists." His collaboration with private and public sector experts is enabling real progress to be made with stunning and heart-warming results for the victims of this terrible affliction. Although hypophosphatasia is thought to only affect one in 100,000 people, McKee says that "research in this area is not just about this disease we are opening doors to the development of treatments for all kinds of problems related to the crystallization of minerals in the body, including seemingly unrelated areas such cardiovascular diseases, arthritis and even kidney stones."

McKee's research program is a concrete example of how university researchers are working with private sector partners as an integral part of Canada's innovative knowledge economy, and the positive outcomes their collaborations can offer. McKee's research is funded in part by the Canadian Institutes of Health Research.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. Boost from McGill, Gates Foundation helps Africans control pharma research
2. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
3. How the public perceives biotech
4. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
5. Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc.
6. Workshops on biotechnology and water for science journalists
7. Oncolytics Biotech, Inc. announces publication of research
8. Genetic Engineering & Biotechnology News reports on advances in miRNA
9. Biotechnology needs 21st century patent system: Expert
10. Genetic Engineering & Biotechnology News reports on cancer biomarkers
11. Food biotechnology: real world challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
(Date:1/21/2016)... PUNE, India , January 21, 2016 /PRNewswire/ ... According to a new market research report "Emotion ... Learning, and Others), Software Tools (Facial Expression, Voice ... and Regions - Global forecast to 2020", published ... Market is expected to reach USD 22.65 Billion ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , ... February 10, 2016 ... ... today announced that it has joined the Human Vaccines Project, a public-private ... diseases and cancer. , The Human Vaccines Project brings together leading ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... states, announced today the promotion of two long-standing principal investigators (PI) to the ... Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics ... Photonics West conference in San Francisco’s Moscone Center from February 16-18, 2016, and ... , These latest InGaAs PIN diode standard packages feature a TO-46 metal can ...
Breaking Biology Technology: